Ascites : aetiology, symptoms and treatment / Eleanor Figueroa, editor.

Format:

Book

Contributor:

Figueroa, Eleanor, editor.

Series:

New Developments in Medical Research

Language:

English

Subjects (All):

Diseases--Causes and theories of causation.

Diseases.

Ascites--Treatment.

Ascites.

Physical Description:

1 online resource (126 p.)

Place of Publication:

New York : Nova Biomedical, 2016.

Summary:

Ascites can result from malignant and non-malignant diseases. The most common cause of non-malignant ascites is related to hepatic cirrhosis. Malignant ascites is associated with a variety of primary tumors and account for 10% of all causes of ascites. This book provides research on the aetiology, symptoms and treatment of ascites. Chapter One summarizes the immune response mechanisms involved in the pathogenesis of human liver cirrhosis at the cellular and molecular levels. Chapter Two summarizes the new findings about the immune response mechanisms and the consequent inflammatory status involved in the pathogenesis of human liver cirrhosis, related with the aetiology, at the cellular and molecular levels. Chapter Three addresses the mechanism of malignant ascites production and covers all clinical aspects of tunneled catheters and tunneled ports including indication, contraindication, device design, technical procedure considerations and, complication. Chapter Four reports information about the management of malignant ascites in ovarian cancer and discusses the involvement of malignant ascites in dissemination, angiogenesis, migration, invasion and apoptosis of ovarian cancer cells.

Contents:

ASCITES: AETIOLOGY, SYMPTOMS AND TREATMENT; ASCITES: AETIOLOGY, SYMPTOMS AND TREATMENT; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: ASCITES IN HUMAN LIVER CIRRHOSIS; ABSTRACT; LIVER CIRRHOSIS; CLINICAL EVOLUTION OF LIVER CIRRHOSIS; Ascites; BACTERIAL TRANSLOCATION; SPONTANEOUS BACTERIAL PERITONITIS; INTESTINAL MICROBIOTA ALTERATIONS IN CIRRHOTIC PATIENTS; PERITONEAL HOST DEFENSE MECHANISMSIN HEALTHY INDIVIDUALS; ALTERATIONS IN PERITONEAL IMMUNERESPONSE IN CIRRHOSIS; Alterations at Cellular Level; Alterations at Molecular Level

INCREASED INTESTINAL PERMEABILITY LEADSTO EXHAUSTION OF THE IMMUNE SYSTEMPITFALLS AND LIMITATIONS OF STUDIESPERFORMED IN LIVER CIRRHOSIS ASCITES; Experimental Animal Models; Etiology; Sample Size and Clinical Stage Variability among Patients; Healthy Control Reference; CONCLUSION; REFERENCES; Chapter 2: DIFFERENCES IN THE INFLAMMATORY STATUS DERIVED ON AETIOLOGY IN HUMAN LIVER CIRRHOSIS; ABSTRACT; INTRODUCTION; NATURAL HISTORY OF LIVER CIRRHOSIS; AETIOLOGY OF CIRRHOSIS; THE DEVELOPMENT OF ASCITES INDUCEDBY LIVER CIRRHOSIS; BACTERIAL TRANSLOCATION IN LIVER CIRRHOSIS

INFLAMMATORY STATUS IN ASCITESOF DECOMPENSATED LIVER CIRRHOSISSTUDIES COMPARING HCV- VSALCOHOL-INDUCED CIRRHOSIS; DIFFERENCES BETWEEN THE PERITONEAL INFLAMMATORY STATUS IN CIRRHOTIC ASCITES INDUCED BY ALCOHOL AND HCV INFECTION; CONCLUSION; REFERENCES; Chapter 3: MINIMALLY INVASIVE MANAGEMENT OF REFRACTORY MALIGNANT ASCITES; ABSTRACT; 1. INTRODUCTION; 2. CAUSES OF REFRACTORY MALIGNANT ASCITES; A. Mechanisms of Production; 3. MINIMALLY INVASIVE MANAGEMENT OF REFRACTORYMALIGNANT ASCITES; A. Historical Background; B. Indications; C. Contraindications; D. Devices; I. Peritoneal Tunneled Catheters

PleurX Drainage System (Figure 1)Aspira® Drainage System (Figure 2); II. Peritoneal Ports; E. Technique; I. Peritoneal Tunneled Catheters; Pre-Procedure Preparation; Intra-Procedure Preparation; Tunneled Catheter Placement Using Ultrasound and FluoroscopicGuidance; Drainage; II. Peritoneal Ports; Pre-Procedure Preparation; Intra-Procedure Preparation; Peritoneal Port Placement Using Ultrasound and FluoroscopicGuidance; Drainage; F. Potential Complications; 4. OUTCOMES; CONCLUSION; REFERENCES; Chapter 4: A LOOK AT THE MANAGEMENT AND USAGE OF MALIGNANT ASCITES IN OVARIAN CANCER; ABSTRACT

INTRODUCTION1. ASCITES; 1.1. Definition of Ascites; 1.2. Malignant Ascites in Ovarian Cancer; 1.3. Management of Malignant Ascites in Ovarian Cancer; 1.3.1. Non-Molecular Therapy; 1.3.1.1. Paracentesis; 1.3.1.2. Catheter Drainage; 1.3.1.3. Diuretic Therapy; 1.3.1.4. Concentrated Ascites Reinfuision Therapy (CART); 1.3.2. Molecular Therapy; 1.3.2.1. Catumaxomab; 1.3.2.2. Anti-Angiogenesis Treatment; 2. ROLE OF MALIGNANT ASCITES IN OVARIAN CANCER; 2.1. Dissemination; 2.1.1. Routes of Dissemination; 2.1.2. Ascites as a Carrier; 2.2. Angiogenesis; 2.2.1. General Information

2.2.2. Angiogenesis and Ascites

Notes:

Description based upon print version of record.

Includes bibliographical references at the end of each chapters and index.

Description based on print version record.

ISBN:

1-63485-479-9